Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DoD Anthrax Vaccine Program May Need Second Manufacturer, Senators Say

Executive Summary

The Department of Defense should consider recruiting a second anthrax vaccine manufacturer to compensate for continued delays experienced by Bioport, Sen. Roberts (R-Kan.) indicated during a Senate Armed Services Committee hearing April 13.

You may also be interested in...



BioPort Anthrax Vaccine Production Could Begin Nov. 15 - HHS' Thompson

BioPort could begin production of anthrax vaccine by Nov. 15 if its Lansing, Mich. facility receives FDA approval, HHS Secretary Tommy Thompson told the Senate Governmental Affairs Committee Oct. 17.

BioPort Anthrax Vaccine Production Could Begin Nov. 15 - HHS' Thompson

BioPort could begin production of anthrax vaccine by Nov. 15 if its Lansing, Mich. facility receives FDA approval, HHS Secretary Tommy Thompson told the Senate Governmental Affairs Committee Oct. 17.

BioPort Anthrax Vaccine Production Data To Be Submitted To FDA By Mid-Oct.

Anthrax vaccine manufacturer BioPort plans to submit data to FDA by Oct. 15 for approval of its renovated Lansing, Mich. plant.

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel